Last reviewed · How we verify
Chronic Heart Failure Following Myocardial Infarction — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Inspra | EPLERENONE | Upjohn | Aldosterone Antagonist [EPC] | Mineralocorticoid receptor | 2002-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Upjohn · 1 drug in Chronic Heart Failure Following Myocardial Infarction
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Chronic Heart Failure Following Myocardial Infarction:
- Chronic Heart Failure Following Myocardial Infarction treatment updates — RSS
- Chronic Heart Failure Following Myocardial Infarction treatment updates — Atom
- Chronic Heart Failure Following Myocardial Infarction treatment updates — JSON
Cite this brief
Drug Landscape (2026). Chronic Heart Failure Following Myocardial Infarction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-heart-failure-following-myocardial-infarction. Accessed 2026-06-10.
Related
- Chronic Heart Failure Following Myocardial Infarction full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing